Monday, February 23, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A COVID-19 variant ‘more infectious than the delta variant’ will hit U.S. in 2-4 months, according to CDC

Dr. Robert Redfield, the former director of the Centers for Disease Control and Prevention, predicted that the fall will have a dark turn in the coronavirus pandemic.

Redfield said on Fox News Channel’s “The Story” that he thinks the coronavirus will continue to replicate quickly among humans, and so the risk of variant evolution is high.

“You know we dealt with the U.K. variant; everyone thought that was pretty bad, it was twice as infectious, but lo and behold three, four months later we had the delta variant and now it’s a dominant variant in the United States,” Redfield said.

He then predicted that there will be another, more dangerous coronavirus variant by the fall.

“Within, you know two, three, four months we’re going to have another variant and that variant’s going to be more infectious than the delta variant,” Redfield said.

Redfield said the coronavirus became one of the most infectious viruses in humans, which allowed it to mutate quicker.

Source: Deseret News

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!